17-Oxo-oestra-p-chinol-(10β) | 549-03-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17-Oxo-oestra-p-chinol-(10β)
• 英文别名: 17-Oxo-oestra-p-chinol-10β；(10S,13S)-10-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione
• CAS: 549-03-1；86900-15-4；109581-81-9
• 化学式: C₁₈H₂₂O₃
• 分子量: 286.371
• InChiKey: RVUDOXUDSXVAEV-VKLUZWIXSA-N

物化性质

• 熔点：
  215-218 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  485.2±45.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Prodrugs for use as ophthalmic agents
  申请人：Prokai Laszlo

  公开号：US20070155711A1

  公开（公告）日：2007-07-05

  The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcomeal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocomeal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
• Prodrugs for Use as Ophthalmic Agents
  申请人：Prokai Laszlo

  公开号：US20070213310A1

  公开（公告）日：2007-09-13

  The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
• US7186707B2
  申请人：——

  公开号：US7186707B2

  公开（公告）日：2007-03-06
• US7534779B2
  申请人：——

  公开号：US7534779B2

  公开（公告）日：2009-05-19
• US7572781B2
  申请人：——

  公开号：US7572781B2

  公开（公告）日：2009-08-11